Princeton Global Asset Management LLC Purchases 2,266 Shares of Eli Lilly and Company $LLY

Princeton Global Asset Management LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 386.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,853 shares of the company’s stock after acquiring an additional 2,266 shares during the period. Princeton Global Asset Management LLC’s holdings in Eli Lilly and Company were worth $3,066,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in LLY. Brighton Jones LLC grew its stake in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the last quarter. Schnieders Capital Management LLC. grew its stake in shares of Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after buying an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $356,000. Finally, Jump Financial LLC purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $6,680,000. Institutional investors own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval of Foundayo creates a new high‑value product opportunity that could add billions to sales and validate Lilly’s oral GLP‑1 strategy. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: CEO Dave Ricks says Lilly is ready to scale production of Foundayo, reducing execution risk and supporting faster commercialization. Eli Lilly CEO Says Company Ready to Scale Production
• Positive Sentiment: Lilly will manufacture the GLP‑1 at a new Houston facility, supporting supply and limiting bottlenecks as demand ramps. Lilly’s $6.5B Houston plant will make its new FDA-approved GLP-1
• Positive Sentiment: Brokerage reaction includes modest price‑target increases and renewed analyst attention, reflecting confidence in Foundayo’s sales potential despite valuation questions. Price Target Raised Following FDA Approval
• Neutral Sentiment: Lilly amended its collaboration with AC Immune to advance next‑generation Tau aggregation inhibitors with IND‑enabling studies planned in 2026 — diversification into neurodegeneration could be material longer term but won’t move near‑term revenue. Eli Lilly Extends AC Immune Tau Pact
• Negative Sentiment: Pricing pressure: Novo Nordisk launched a lower‑priced Wegovy HD at about a 40% lower cash price than Lilly’s offering, raising concerns that price competition could blunt Foundayo’s revenue and margins. Novo Nordisk Unveils $399 Wegovy HD
• Negative Sentiment: Market commentary flags a broader GLP‑1 price war and side‑effect/competition concerns that have driven short‑term profit‑taking and tempered the stock’s post‑approval rally. Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod

Analyst Upgrades and Downgrades

LLY has been the topic of several recent research reports. TD Cowen upped their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Scotiabank restated an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Loop Capital set a $1,200.00 price target on Eli Lilly and Company in a research note on Tuesday, February 10th. Jefferies Financial Group set a $1,300.00 price target on Eli Lilly and Company and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Daiwa Securities Group upped their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,222.22.

Eli Lilly and Company Stock Performance

LLY stock opened at $930.08 on Wednesday. The company has a market cap of $878.76 billion, a P/E ratio of 40.53, a price-to-earnings-growth ratio of 1.09 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The stock’s fifty day moving average price is $988.75 and its 200-day moving average price is $973.25.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same period last year, the firm earned $5.32 EPS. Eli Lilly and Company’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.